Dr. Dubin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1549 Tanglewood Dr
West Chester, PA 19380Phone+1 610-651-0827
Education & Training
University of Pennsylvania Health SystemFellowship, Infectious Disease, 1989 - 1991
University of ColoradoResidency, Internal Medicine, 1983 - 1986
Perelman School of Medicine at the University of PennsylvaniaClass of 1983
Certifications & Licensure
PA State Medical License 1987 - 2024
CO State Medical License 1985 - 1989- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 362 citationsEnhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt onlySandra L. Giannini, Emmanuel Hanon, Philippe Moris, Marcelle Van Mechelen, Sandra Morel
Vaccine. 2006-08-14 - 1121 citationsEfficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M. Harper, Eduardo L. Franco, Cosette M. Wheeler, Daron G. Ferris, D. G. Jenkins
Lancet. 2004-11-13 - 1103 citationsSustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialDiane M. Harper, Eduardo L. Franco, Cosette M. Wheeler, Anna-Barbara Moscicki, Barbara Romanowski
Lancet. 2006-04-15
Press Mentions
![Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union | Pages Da](https://doximity-res.cloudinary.com/image/upload/v1548182770/gxs6nltgxdhkzaxlty6p.png)
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union | Pages DaDecember 8th, 2022- Takeda Dengue Vaccine Recommended for Approval by European CommitteeOctober 17th, 2022
- Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic CountriesOctober 14th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
